DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority randomized controlled trial, embedded in the TREAT NL registry.
Key facts
- Where
- Almere, Amsterdam és Rotterdam, HollandiaSee the 3 sites
- Phase
- 4. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Hollandia
- Flevoziekenhuis StichtingAlmere, HollandiaNo longer taking part
- Amsterdam UMCAmsterdam, HollandiaNo longer taking part
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, HollandiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC
- Trial code
- EU 2023-504171-24-00
- Record updated
- 2024. december 2.
- Original description
To evaluate and compare the efficacy of dupilumab 300 mg every 2 weeks, every 3 weeks and every 4 weeks, 16 weeks after randomization.Read full original descriptionShow less
To evaluate and compare the efficacy of dupilumab 300 mg every 2 weeks, every 3 weeks and every 4 weeks, 16 weeks after randomization.
Inclusion: The subject is an adult; The subject has a diagnosis of atopic eczema; The subject receives dupilumab 300 mg every 2 weeks for the treatment of atopic eczema; The subject has controlled disease according to the Treat-to-Target criteria; The subject has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol.
Exclusion: The subject uses or initiates other systemic immunomodulating therapy for atopic eczema or another diagnosis.